Device Trial Radar · NCT06456554
Acellular Dermal Matrix Investigation in Breast Reconstruction
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
467
Planned (sponsor's estimate)
Start
Nov 22, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- RTI SurgicalNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- MCRA
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective, multi-center, dual-arm non-randomized clinical study in females undergoing a two-stage breast reconstruction using a pre-pectoral technique.
Conditions
- Breast Reconstruction
Interventions
Acellular Dermal Matrix (Cortiva Tissue Matrix)Device
non-crosslinked dermis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of major adverse eventsTime frame: 12 months
- Health related quality of lifeTime frame: 12 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of Arkansas
Little Rock, Arkansas · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.